Cipla (CIPLA) — Announcement

📢 Key Event
Cipla receives U.S. FDA approval for generic Advair Diskus

🔮 What's Next
Q2 of FY 2026-27 U.S. launch

Cipla announced U.S. FDA approval for its generic version of Advair Diskus across all three strengths, targeting a Q2 FY2026-27 U.S. launch and marking its first dry powder inhaler approval from its New York facility, expanding its complex respiratory portfolio in a $908 million market.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

💡 Ask AI about this filing

"When will the generic Advair launch in the U.S. market?" "What is the expected revenue contribution from this product?" "How does this approval affect Cipla's U.S. manufacturing capacity utilization?"

Ask AI Free →

📊 More CIPLA filings

See all CIPLA filings →

🔥 Also filed on 27 July 2026

FAIRCHEMOR Fairchem Organics Limited Financial Results MPHASIS MphasiS Limited Insider Trading NTPC NTPC Limited Corporate Action CCL CCL Products (India) Limited Corporate Action ITI ITI Limited Announcement SHRIRAMFIN Shriram Finance Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.